Article
BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.
Journal of experimental & clinical cancer research : CR - 25 Mar 2026
Kotarac Anna, Osumi Hiroki, Malt Alexander, Alp Keziban Merve, Jarosch Armin, Werner Johannes, Benary Manuela, Neumann Christopher C M, Yao Ryoji, Mertins Philipp, Eils Roland, Beule Dieter, Sers Christine, Keilholz Ulrich, Ishaque Naveed, Stintzing Sebastian, Vecchione Loredana
Abstract excerpt
BACKGROUND: Drug resistance and lack of predicting biomarkers are a major challenge for cancer therapy. The combination of a BRAF inhibitor (BRAFi) together with an anti-EGFR inhibitor (EGFRi) represents a standard of care approach in BRAFV600E metastatic colorectal cancer (mCRC) patients. However, predictive biomarkers of sensitivity, that could support patient selection for treatment with this combination, are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
